ΠΠΎΠ΅Π½Π½ΡΠ΅ ΡΠΈΠ½Ρ ΠΈ Π·Π½Π°ΠΊΠΈ
ΠΠ΅ΡΡΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΡΠ°Π½Π³ΠΈ Π²ΠΎΠ΅Π½Π½ΠΎΡΠ»ΡΠΆΠ°ΡΠΈΡ ΡΡΠ°Π½ΡΡΠ·ΡΠΊΠΎΠΉ Π°ΡΠΌΠΈΠΈ Π΄Π΅Π»ΠΈΠ»ΠΈΡΡ Π½Π° Π³Π΅Π½Π΅ΡΠ°Π»ΡΡΠΊΠΈΠ΅, ΠΎΡΠΈΡΠ΅ΡΡΠΊΠΈΠ΅ ΠΈ ΡΠ½ΡΠ΅Ρ-ΠΎΡΠΈΡΠ΅ΡΡΠΊΠΈΠ΅.via forma full 5 https://ift.tt/lZ0k7YD Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
ΠΠ΅ΡΡΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΡΠ°Π½Π³ΠΈ Π²ΠΎΠ΅Π½Π½ΠΎΡΠ»ΡΠΆΠ°ΡΠΈΡ ΡΡΠ°Π½ΡΡΠ·ΡΠΊΠΎΠΉ Π°ΡΠΌΠΈΠΈ Π΄Π΅Π»ΠΈΠ»ΠΈΡΡ Π½Π° Π³Π΅Π½Π΅ΡΠ°Π»ΡΡΠΊΠΈΠ΅, ΠΎΡΠΈΡΠ΅ΡΡΠΊΠΈΠ΅ ΠΈ ΡΠ½ΡΠ΅Ρ-ΠΎΡΠΈΡΠ΅ΡΡΠΊΠΈΠ΅.via forma full 5 https://ift.tt/lZ0k7YD Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠΎΠ΅Π½Π½ΡΠ΅ ΡΠΈΠ½Ρ ΠΈ Π·Π½Π°ΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π°ΡΠΌΠΈΠΈ ΠΠ°ΠΏΠΎΠ»Π΅ΠΎΠ½Π°
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠΎΠ΅Π½Π½ΡΠ΅ ΡΠΈΠ½Ρ ΠΈ Π·Π½Π°ΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π°ΡΠΌΠΈΠΈ ΠΠ°ΠΏΠΎΠ»Π΅ΠΎΠ½Π° Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ
ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΠΎΡ ΡΠ΅Ρ , ΠΊΠΎΡΠΎΡΡΠ΅ Π½ΠΎΡΡΡ ΠΎΡΠΈΡΠ΅ΡΡ, ΠΊΠ°ΠΊ Π²Π½Π΅ΡΠ½Π΅, ΡΠ°ΠΊ ΠΈ ΠΏΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΡ. ΠΡΡΡΠ°Π½Ρ - ΡΡΠΎ Π΄ΠΎΠ»ΠΆΠ½ΠΎΡΡΡ...via forma full 5 https://ift.tt/wnDvCze Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΠΎΡ ΡΠ΅Ρ , ΠΊΠΎΡΠΎΡΡΠ΅ Π½ΠΎΡΡΡ ΠΎΡΠΈΡΠ΅ΡΡ, ΠΊΠ°ΠΊ Π²Π½Π΅ΡΠ½Π΅, ΡΠ°ΠΊ ΠΈ ΠΏΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΡ. ΠΡΡΡΠ°Π½Ρ - ΡΡΠΎ Π΄ΠΎΠ»ΠΆΠ½ΠΎΡΡΡ...via forma full 5 https://ift.tt/wnDvCze Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΡΡΡΠ°Π½ΡΡΠΊΠΈΠ΅ ΠΏΠΎΠ³ΠΎΠ½Ρ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ*
Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½Π°Ρ ΡΠ»ΡΠΆΠ±Π° Π²ΠΎΠΉΡΠΊ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π³Π²Π°ΡΠ΄ΠΈΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ (Π ΠΎΡΠ³Π²Π°ΡΠ΄ΠΈΡ) β ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΡΠΉ ΠΎΡΠ³Π°Π½ ΠΈΡΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π²Π»Π°ΡΡΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ, ΡΠΏΠ΅ΡΡΠ»ΡΠΆΠ±Π°...via forma full 5 https://ift.tt/MYxFaSg Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3581058.html)
Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½Π°Ρ ΡΠ»ΡΠΆΠ±Π° Π²ΠΎΠΉΡΠΊ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π³Π²Π°ΡΠ΄ΠΈΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ (Π ΠΎΡΠ³Π²Π°ΡΠ΄ΠΈΡ) β ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΡΠΉ ΠΎΡΠ³Π°Π½ ΠΈΡΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π²Π»Π°ΡΡΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ, ΡΠΏΠ΅ΡΡΠ»ΡΠΆΠ±Π°...via forma full 5 https://ift.tt/MYxFaSg Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3581058.html)
Forma-Odezhda
ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π³Π²Π°ΡΠ΄ΠΈΡ Π Π€ (Π ΠΎΡΠ³Π²Π°ΡΠ΄ΠΈΡ)
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π³Π²Π°ΡΠ΄ΠΈΡ Π Π€ (Π ΠΎΡΠ³Π²Π°ΡΠ΄ΠΈΡ) Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ
Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½Π°Ρ ΡΠ»ΡΠΆΠ±Π° Π²ΠΎΠΉΡΠΊ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π³Π²Π°ΡΠ΄ΠΈΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ (Π ΠΎΡΠ³Π²Π°ΡΠ΄ΠΈΡ) β ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΡΠΉ ΠΎΡΠ³Π°Π½ ΠΈΡΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π²Π»Π°ΡΡΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ, ΡΠΏΠ΅ΡΡΠ»ΡΠΆΠ±Π°...via forma full 5 https://ift.tt/MYxFaSg Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½Π°Ρ ΡΠ»ΡΠΆΠ±Π° Π²ΠΎΠΉΡΠΊ Π½Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ Π³Π²Π°ΡΠ΄ΠΈΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ (Π ΠΎΡΠ³Π²Π°ΡΠ΄ΠΈΡ) β ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΡΠΉ ΠΎΡΠ³Π°Π½ ΠΈΡΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π²Π»Π°ΡΡΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ, ΡΠΏΠ΅ΡΡΠ»ΡΠΆΠ±Π°...via forma full 5 https://ift.tt/MYxFaSg Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π³Π²Π°ΡΠ΄ΠΈΡ Π Π€ (Π ΠΎΡΠ³Π²Π°ΡΠ΄ΠΈΡ)
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ°ΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ Π³Π²Π°ΡΠ΄ΠΈΡ Π Π€ (Π ΠΎΡΠ³Π²Π°ΡΠ΄ΠΈΡ) Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ°*
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠΈ ΠΠ΅ΡΠΌΠ°Π½ΠΈΠΈ ΠΠ· Π²ΡΠ΅Ρ Π·Π°ΠΏΠ°Π΄Π½ΡΡ ΡΡΡΠ°Π½ ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ ΠΈΠΌΠ΅Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΠΎΠΏΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΡ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠ½ΡΡ ΡΠ°ΡΡΠ²Π΅ΡΠΎΠΊ. Π‘ΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠ΅ΡΠ²ΡΠΉ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆ Ρ Π½Π΅ΠΌΡΠ΅Π² ΠΏΠΎΡΠ²ΠΈΠ»ΡΡ Π΅ΡΠ΅ Π² ΠΠ΅ΡΠ²ΡΡ ΠΌΠΈΡΠΎΠ²ΡΡ.via forma full 5 https://ift.tt/vG0KueX Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.tumblr.com/post/737411780470505472)
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠΈ ΠΠ΅ΡΠΌΠ°Π½ΠΈΠΈ ΠΠ· Π²ΡΠ΅Ρ Π·Π°ΠΏΠ°Π΄Π½ΡΡ ΡΡΡΠ°Π½ ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ ΠΈΠΌΠ΅Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΠΎΠΏΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΡ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠ½ΡΡ ΡΠ°ΡΡΠ²Π΅ΡΠΎΠΊ. Π‘ΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠ΅ΡΠ²ΡΠΉ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆ Ρ Π½Π΅ΠΌΡΠ΅Π² ΠΏΠΎΡΠ²ΠΈΠ»ΡΡ Π΅ΡΠ΅ Π² ΠΠ΅ΡΠ²ΡΡ ΠΌΠΈΡΠΎΠ²ΡΡ.via forma full 5 https://ift.tt/vG0KueX Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.tumblr.com/post/737411780470505472)
Forma-Odezhda
ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ°
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ° Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ°
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠΈ ΠΠ΅ΡΠΌΠ°Π½ΠΈΠΈ ΠΠ· Π²ΡΠ΅Ρ Π·Π°ΠΏΠ°Π΄Π½ΡΡ ΡΡΡΠ°Π½ ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ ΠΈΠΌΠ΅Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΠΎΠΏΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΡ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠ½ΡΡ ΡΠ°ΡΡΠ²Π΅ΡΠΎΠΊ. Π‘ΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠ΅ΡΠ²ΡΠΉ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆ Ρ Π½Π΅ΠΌΡΠ΅Π² ΠΏΠΎΡΠ²ΠΈΠ»ΡΡ Π΅ΡΠ΅ Π² ΠΠ΅ΡΠ²ΡΡ ΠΌΠΈΡΠΎΠ²ΡΡ.via forma full 5 https://ift.tt/vG0KueX Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠΈ ΠΠ΅ΡΠΌΠ°Π½ΠΈΠΈ ΠΠ· Π²ΡΠ΅Ρ Π·Π°ΠΏΠ°Π΄Π½ΡΡ ΡΡΡΠ°Π½ ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ ΠΈΠΌΠ΅Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΠΎΠΏΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΡ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠ½ΡΡ ΡΠ°ΡΡΠ²Π΅ΡΠΎΠΊ. Π‘ΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠ΅ΡΠ²ΡΠΉ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆ Ρ Π½Π΅ΠΌΡΠ΅Π² ΠΏΠΎΡΠ²ΠΈΠ»ΡΡ Π΅ΡΠ΅ Π² ΠΠ΅ΡΠ²ΡΡ ΠΌΠΈΡΠΎΠ²ΡΡ.via forma full 5 https://ift.tt/vG0KueX Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ°
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ° Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*ΠΠΎΡΠ΅ΠΌΡ ΡΠΈΠ»ΡΠΌΡ ΠΎ ΠΠ΅ΡΡΠΈ ΠΠΆΠ΅ΠΊΡΠΎΠ½Π΅ ΡΠ°Π·ΠΎΡΠ°ΡΠΎΠ²Π°Π»ΠΈ ΠΈ ΠΊΠ°ΠΊ ΡΠ΅ΡΠΈΠ°Π» ΠΌΠΎΠΆΠ΅Ρ ΡΡΠΎ ΠΈΡΠΏΡΠ°Π²ΠΈΡΡ*
Π Π²ΠΎΡ Ρ ΠΊΠ½ΠΈΠ³ Π±ΠΎΠ»ΡΡΠ°Ρ ΡΠ°Π½-Π±Π°Π·Π°!
[Read more...](https://burninghut.ru/persi-dzhekson/?utm_source=lifehacker.ru&utm_medium=referral&utm_campaign=teaser&utm_content=persi-dzhekson)
Π Π²ΠΎΡ Ρ ΠΊΠ½ΠΈΠ³ Π±ΠΎΠ»ΡΡΠ°Ρ ΡΠ°Π½-Π±Π°Π·Π°!
[Read more...](https://burninghut.ru/persi-dzhekson/?utm_source=lifehacker.ru&utm_medium=referral&utm_campaign=teaser&utm_content=persi-dzhekson)
*Nike slumps after cutting full-year sales forecast on sportswear weakness*
Updated at 7:36 AM EST Nike (NKE) - Get Free Report shares fell sharply in early Friday trading after the sportswear giant issued a muted full-year revenue outlook and cost-cutting plan that offset a solid fiscal-second-quarter earnings report. Nike said for the three months ended in November came in at $1.03 a share, up 21% from the year-earlier period and firmly ahead of the Wall Street consensus forecast of an 85-cent profit. Group revenue, however, rose only 1% from last year earlier to $13.4 billion, just shy of analysts' estimates of a $13.43 billion tally. China revenue was also light of forecasts, rising 8% to $1.86 billion, while North America revenue was down 3.5% to $5.63 billion. Gross margin improved modestly, widening 40 basis points (0.4 percentage point) from the prior quarter and 1.7 percentage points from a year earlier to 44.6%, thanks to fewer markdowns and cheaper shipping costs.Nike seeks to cut $2 billion of costs Looking into the second half of its financial year, Nike sees revenue growing by a similar amount compared with its autumn forecast of 'mid-single-digit-percent' gains, thanks in part to weakness in China and "increased macro headwinds." As a result, Nike said, it was looking to cut another $2 billion in costs over the next three years, with a focus on supply-chain efficiency, more automation and mid-management job cuts. "Last quarter, as I provided guidance, I highlighted a number of risks in our operating environment, including the effects of a stronger U.S. dollar on foreign-currency translation, consumer demand over the holiday season, and our second-half wholesale order books," chief financial officer Matt Friend told investors on a conference call late Thursday. "Looking forward, the impact of these risks is becoming clearer, and as a result, we are adjusting our full-year financial outlook," he added. "As we move forward, our focus is building a faster, more efficient Nike and embracing the opportunities in front of us to accelerate sustainable and more profitable growth." Nike shares were marked 12.8% lower in premarket trading to indicate an opening bell price of $106.90 each. Foot Locker (FL) - Get Free Report, which relies heavily on Nike for its retail sales, was marked 7.12% lower at $30 each while German sportswear rival Adidas (ADDYY) - Get Free Report slumped 6% in Frankfurt. "Nike posted slightly softer than expected top-line results amid a difficult macro, with gross margin expansion and timing shifts in expenses led to a solid earnings beat," said KeyBanc Capital Markets analyst Ashley Owens. She carries a sector weight rating on the stock. "We are encouraged by momentum in (Asia and Latin America) but a strong second-half recovery in China looks to be out of focus due to increasing macro headwinds, and helped drive a downward revision to guidance, and we think reduced guidance implies ongoing uncertainty in the near term," she added.Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
[Read more...](https://www.thestreet.com/investing/stocks/nike-slumps-after-cutting-full-year-sales-forecast-on-sportswear-weakness)
Updated at 7:36 AM EST Nike (NKE) - Get Free Report shares fell sharply in early Friday trading after the sportswear giant issued a muted full-year revenue outlook and cost-cutting plan that offset a solid fiscal-second-quarter earnings report. Nike said for the three months ended in November came in at $1.03 a share, up 21% from the year-earlier period and firmly ahead of the Wall Street consensus forecast of an 85-cent profit. Group revenue, however, rose only 1% from last year earlier to $13.4 billion, just shy of analysts' estimates of a $13.43 billion tally. China revenue was also light of forecasts, rising 8% to $1.86 billion, while North America revenue was down 3.5% to $5.63 billion. Gross margin improved modestly, widening 40 basis points (0.4 percentage point) from the prior quarter and 1.7 percentage points from a year earlier to 44.6%, thanks to fewer markdowns and cheaper shipping costs.Nike seeks to cut $2 billion of costs Looking into the second half of its financial year, Nike sees revenue growing by a similar amount compared with its autumn forecast of 'mid-single-digit-percent' gains, thanks in part to weakness in China and "increased macro headwinds." As a result, Nike said, it was looking to cut another $2 billion in costs over the next three years, with a focus on supply-chain efficiency, more automation and mid-management job cuts. "Last quarter, as I provided guidance, I highlighted a number of risks in our operating environment, including the effects of a stronger U.S. dollar on foreign-currency translation, consumer demand over the holiday season, and our second-half wholesale order books," chief financial officer Matt Friend told investors on a conference call late Thursday. "Looking forward, the impact of these risks is becoming clearer, and as a result, we are adjusting our full-year financial outlook," he added. "As we move forward, our focus is building a faster, more efficient Nike and embracing the opportunities in front of us to accelerate sustainable and more profitable growth." Nike shares were marked 12.8% lower in premarket trading to indicate an opening bell price of $106.90 each. Foot Locker (FL) - Get Free Report, which relies heavily on Nike for its retail sales, was marked 7.12% lower at $30 each while German sportswear rival Adidas (ADDYY) - Get Free Report slumped 6% in Frankfurt. "Nike posted slightly softer than expected top-line results amid a difficult macro, with gross margin expansion and timing shifts in expenses led to a solid earnings beat," said KeyBanc Capital Markets analyst Ashley Owens. She carries a sector weight rating on the stock. "We are encouraged by momentum in (Asia and Latin America) but a strong second-half recovery in China looks to be out of focus due to increasing macro headwinds, and helped drive a downward revision to guidance, and we think reduced guidance implies ongoing uncertainty in the near term," she added.Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
[Read more...](https://www.thestreet.com/investing/stocks/nike-slumps-after-cutting-full-year-sales-forecast-on-sportswear-weakness)
TheStreet
Nike slumps after cutting full-year sales forecast on sportswear weakness
Nike said it sees weakness in sportswear demand, as well as currency headwinds, for the second half of its financial year.
*This Game-Changing Sleep Mask Works Better Than Blackout Curtains and Is My Secret to a Full Nightβs Sleep*
I wasn't an eye mask person before, but I am now! READ MORE...
[Read more...](https://www.apartmenttherapy.com/manta-sleep-mask-review-ll-37357908?utm_source=RSS&utm_medium=feed&utm_campaign=Category%2FChannel%3A+main)
I wasn't an eye mask person before, but I am now! READ MORE...
[Read more...](https://www.apartmenttherapy.com/manta-sleep-mask-review-ll-37357908?utm_source=RSS&utm_medium=feed&utm_campaign=Category%2FChannel%3A+main)
Nike slumps after cutting full-year sales forecast on sportswear weakness
Updated at 7:36 AM EST Nike (NKE) - Get Free Report shares fell sharply in early Friday trading after the sportswear giant issued a muted full-year revenue outlook and cost-cutting plan that offset a solid fiscal-second-quarter earnings report. Nike said for the three months ended in November came in at $1.03 a share, up 21% from the year-earlier period and firmly ahead of the Wall Street consensus forecast of an 85-cent profit. Group revenue, however, rose only 1% from last year earlier to $13.4 billion, just shy of analysts' estimates of a $13.43 billion tally. China revenue was also light of forecasts, rising 8% to $1.86 billion, while North America revenue was down 3.5% to $5.63 billion. Gross margin improved modestly, widening 40 basis points (0.4 percentage point) from the prior quarter and 1.7 percentage points from a year earlier to 44.6%, thanks to fewer markdowns and cheaper shipping costs.Nike seeks to cut $2 billion of costs Looking into the second half of its financial year, Nike sees revenue growing by a similar amount compared with its autumn forecast of 'mid-single-digit-percent' gains, thanks in part to weakness in China and "increased macro headwinds." As a result, Nike said, it was looking to cut another $2 billion in costs over the next three years, with a focus on supply-chain efficiency, more automation and mid-management job cuts. "Last quarter, as I provided guidance, I highlighted a number of risks in our operating environment, including the effects of a stronger U.S. dollar on foreign-currency translation, consumer demand over the holiday season, and our second-half wholesale order books," chief financial officer Matt Friend told investors on a conference call late Thursday. "Looking forward, the impact of these risks is becoming clearer, and as a result, we are adjusting our full-year financial outlook," he added. "As we move forward, our focus is building a faster, more efficient Nike and embracing the opportunities in front of us to accelerate sustainable and more profitable growth." Nike shares were marked 12.8% lower in premarket trading to indicate an opening bell price of $106.90 each. Foot Locker (FL) - Get Free Report, which relies heavily on Nike for its retail sales, was marked 7.12% lower at $30 each while German sportswear rival Adidas (ADDYY) - Get Free Report slumped 6% in Frankfurt. "Nike posted slightly softer than expected top-line results amid a difficult macro, with gross margin expansion and timing shifts in expenses led to a solid earnings beat," said KeyBanc Capital Markets analyst Ashley Owens. She carries a sector weight rating on the stock. "We are encouraged by momentum in (Asia and Latin America) but a strong second-half recovery in China looks to be out of focus due to increasing macro headwinds, and helped drive a downward revision to guidance, and we think reduced guidance implies ongoing uncertainty in the near term," she added.Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
Read more...
Updated at 7:36 AM EST Nike (NKE) - Get Free Report shares fell sharply in early Friday trading after the sportswear giant issued a muted full-year revenue outlook and cost-cutting plan that offset a solid fiscal-second-quarter earnings report. Nike said for the three months ended in November came in at $1.03 a share, up 21% from the year-earlier period and firmly ahead of the Wall Street consensus forecast of an 85-cent profit. Group revenue, however, rose only 1% from last year earlier to $13.4 billion, just shy of analysts' estimates of a $13.43 billion tally. China revenue was also light of forecasts, rising 8% to $1.86 billion, while North America revenue was down 3.5% to $5.63 billion. Gross margin improved modestly, widening 40 basis points (0.4 percentage point) from the prior quarter and 1.7 percentage points from a year earlier to 44.6%, thanks to fewer markdowns and cheaper shipping costs.Nike seeks to cut $2 billion of costs Looking into the second half of its financial year, Nike sees revenue growing by a similar amount compared with its autumn forecast of 'mid-single-digit-percent' gains, thanks in part to weakness in China and "increased macro headwinds." As a result, Nike said, it was looking to cut another $2 billion in costs over the next three years, with a focus on supply-chain efficiency, more automation and mid-management job cuts. "Last quarter, as I provided guidance, I highlighted a number of risks in our operating environment, including the effects of a stronger U.S. dollar on foreign-currency translation, consumer demand over the holiday season, and our second-half wholesale order books," chief financial officer Matt Friend told investors on a conference call late Thursday. "Looking forward, the impact of these risks is becoming clearer, and as a result, we are adjusting our full-year financial outlook," he added. "As we move forward, our focus is building a faster, more efficient Nike and embracing the opportunities in front of us to accelerate sustainable and more profitable growth." Nike shares were marked 12.8% lower in premarket trading to indicate an opening bell price of $106.90 each. Foot Locker (FL) - Get Free Report, which relies heavily on Nike for its retail sales, was marked 7.12% lower at $30 each while German sportswear rival Adidas (ADDYY) - Get Free Report slumped 6% in Frankfurt. "Nike posted slightly softer than expected top-line results amid a difficult macro, with gross margin expansion and timing shifts in expenses led to a solid earnings beat," said KeyBanc Capital Markets analyst Ashley Owens. She carries a sector weight rating on the stock. "We are encouraged by momentum in (Asia and Latin America) but a strong second-half recovery in China looks to be out of focus due to increasing macro headwinds, and helped drive a downward revision to guidance, and we think reduced guidance implies ongoing uncertainty in the near term," she added.Action Alerts PLUS offers expert portfolio guidance to help you make informed investing decisions. Sign up now.
Read more...
TheStreet
Nike slumps after cutting full-year sales forecast on sportswear weakness
Nike said it sees weakness in sportswear demand, as well as currency headwinds, for the second half of its financial year.
*Karuna Therapeutics soars after $14 billion takeover by Bristol Myers*
Karuna Therapeutics (KRTX) - Get Free Report shares soared Friday after the neurological-drug specialists agreed to a $14 billion takeover by pharma giant Bristol Myers Squibb (BMY) - Get Free Report. Bristol Myers said it would pay $330 a share cash for the Boston drugmaker, a 53% premium to its Thursday closing price, a deal that values the group at around $14 billion. Karuna focuses on treatments for patients suffering psychiatric and neurological conditions. Last month the Food and Drug Administration accepted its new-drug application for KarXT, a drug designed to treat schizophrenia. βSchizophrenia and Alzheimerβs disease psychosis affect millions of people worldwide, with limited to no treatment options," said Karuna's chief medical officer, Samit Hirawat. "KarXTβs novel mechanism has resulted in a transformational profile in schizophrenia, with compelling efficacy and a differentiated safety profile.β βKarXT also has the potential to deliver meaningful benefits to patients as an adjunctive treatment for patients with schizophrenia and as a first treatment for Alzheimerβs disease psychosis,β he added. Karuna Therapeutics shares were marked 47.5% higher in premarket trading immediately following news of the takeover to indicate an opening bell price of $317.50 Bristol Myers shares, meanwhile, slipped 1.6% to $59.45 each.Bristol Myers: Second major deal of '23 The deal marks the second major acquisition for Bristol Myers this year, following its $5.8 billion purchase of San Diego cancer-drug specialists Mirati Therapeutics (MRTX) - Get Free Report in October. βThere are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space," said Bristol Myers CEO Chris Boerner. "We expect KarXT to enhance our growth through the late 2020s and into the next decade." βThis transaction fits squarely within our business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need," he added. Get investment guidance from trusted portfolio managers without the management fees. Sign up for Action Alerts PLUS now.
[Read more...](https://www.thestreet.com/investing/stocks/karuna-therapeutics-soars-after-14-billion-takeover-by-bristol-myers)
Karuna Therapeutics (KRTX) - Get Free Report shares soared Friday after the neurological-drug specialists agreed to a $14 billion takeover by pharma giant Bristol Myers Squibb (BMY) - Get Free Report. Bristol Myers said it would pay $330 a share cash for the Boston drugmaker, a 53% premium to its Thursday closing price, a deal that values the group at around $14 billion. Karuna focuses on treatments for patients suffering psychiatric and neurological conditions. Last month the Food and Drug Administration accepted its new-drug application for KarXT, a drug designed to treat schizophrenia. βSchizophrenia and Alzheimerβs disease psychosis affect millions of people worldwide, with limited to no treatment options," said Karuna's chief medical officer, Samit Hirawat. "KarXTβs novel mechanism has resulted in a transformational profile in schizophrenia, with compelling efficacy and a differentiated safety profile.β βKarXT also has the potential to deliver meaningful benefits to patients as an adjunctive treatment for patients with schizophrenia and as a first treatment for Alzheimerβs disease psychosis,β he added. Karuna Therapeutics shares were marked 47.5% higher in premarket trading immediately following news of the takeover to indicate an opening bell price of $317.50 Bristol Myers shares, meanwhile, slipped 1.6% to $59.45 each.Bristol Myers: Second major deal of '23 The deal marks the second major acquisition for Bristol Myers this year, following its $5.8 billion purchase of San Diego cancer-drug specialists Mirati Therapeutics (MRTX) - Get Free Report in October. βThere are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space," said Bristol Myers CEO Chris Boerner. "We expect KarXT to enhance our growth through the late 2020s and into the next decade." βThis transaction fits squarely within our business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need," he added. Get investment guidance from trusted portfolio managers without the management fees. Sign up for Action Alerts PLUS now.
[Read more...](https://www.thestreet.com/investing/stocks/karuna-therapeutics-soars-after-14-billion-takeover-by-bristol-myers)
TheStreet
Karuna Therapeutics soars after $14 billion takeover by Bristol Myers
Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimer's drugmaker Karuna Therapeutics for $14 billion.
Karuna Therapeutics soars after $14 billion takeover by Bristol Myers
Karuna Therapeutics (KRTX) - Get Free Report shares soared Friday after the neurological-drug specialists agreed to a $14 billion takeover by pharma giant Bristol Myers Squibb (BMY) - Get Free Report. Bristol Myers said it would pay $330 a share cash for the Boston drugmaker, a 53% premium to its Thursday closing price, a deal that values the group at around $14 billion. Karuna focuses on treatments for patients suffering psychiatric and neurological conditions. Last month the Food and Drug Administration accepted its new-drug application for KarXT, a drug designed to treat schizophrenia. βSchizophrenia and Alzheimerβs disease psychosis affect millions of people worldwide, with limited to no treatment options," said Karuna's chief medical officer, Samit Hirawat. "KarXTβs novel mechanism has resulted in a transformational profile in schizophrenia, with compelling efficacy and a differentiated safety profile.β βKarXT also has the potential to deliver meaningful benefits to patients as an adjunctive treatment for patients with schizophrenia and as a first treatment for Alzheimerβs disease psychosis,β he added. Karuna Therapeutics shares were marked 47.5% higher in premarket trading immediately following news of the takeover to indicate an opening bell price of $317.50 Bristol Myers shares, meanwhile, slipped 1.6% to $59.45 each.Bristol Myers: Second major deal of '23 The deal marks the second major acquisition for Bristol Myers this year, following its $5.8 billion purchase of San Diego cancer-drug specialists Mirati Therapeutics (MRTX) - Get Free Report in October. βThere are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space," said Bristol Myers CEO Chris Boerner. "We expect KarXT to enhance our growth through the late 2020s and into the next decade." βThis transaction fits squarely within our business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need," he added. Get investment guidance from trusted portfolio managers without the management fees. Sign up for Action Alerts PLUS now.
Read more...
Karuna Therapeutics (KRTX) - Get Free Report shares soared Friday after the neurological-drug specialists agreed to a $14 billion takeover by pharma giant Bristol Myers Squibb (BMY) - Get Free Report. Bristol Myers said it would pay $330 a share cash for the Boston drugmaker, a 53% premium to its Thursday closing price, a deal that values the group at around $14 billion. Karuna focuses on treatments for patients suffering psychiatric and neurological conditions. Last month the Food and Drug Administration accepted its new-drug application for KarXT, a drug designed to treat schizophrenia. βSchizophrenia and Alzheimerβs disease psychosis affect millions of people worldwide, with limited to no treatment options," said Karuna's chief medical officer, Samit Hirawat. "KarXTβs novel mechanism has resulted in a transformational profile in schizophrenia, with compelling efficacy and a differentiated safety profile.β βKarXT also has the potential to deliver meaningful benefits to patients as an adjunctive treatment for patients with schizophrenia and as a first treatment for Alzheimerβs disease psychosis,β he added. Karuna Therapeutics shares were marked 47.5% higher in premarket trading immediately following news of the takeover to indicate an opening bell price of $317.50 Bristol Myers shares, meanwhile, slipped 1.6% to $59.45 each.Bristol Myers: Second major deal of '23 The deal marks the second major acquisition for Bristol Myers this year, following its $5.8 billion purchase of San Diego cancer-drug specialists Mirati Therapeutics (MRTX) - Get Free Report in October. βThere are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio in the space," said Bristol Myers CEO Chris Boerner. "We expect KarXT to enhance our growth through the late 2020s and into the next decade." βThis transaction fits squarely within our business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need," he added. Get investment guidance from trusted portfolio managers without the management fees. Sign up for Action Alerts PLUS now.
Read more...
TheStreet
Karuna Therapeutics soars after $14 billion takeover by Bristol Myers
Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimer's drugmaker Karuna Therapeutics for $14 billion.
*Π€ΠΈΠ½Π°Π½ΡΠΎΠ²ΡΠ΅ ΡΠΊΡΠΏΠ΅ΡΡΡ Π²ΡΡΡΠ½ΠΈΠ»ΠΈ, ΡΠΊΠΎΠ»ΡΠΊΠΎ Π·Π°ΡΠ°Π±Π°ΡΡΠ²Π°Π»ΠΈ ΡΠΎΠ΄ΠΈΡΠ΅Π»ΠΈ ΠΠ΅Π²ΠΈΠ½Π° ΠΈΠ· ΡΠΈΠ»ΡΠΌΠ° Β«ΠΠ΄ΠΈΠ½ Π΄ΠΎΠΌΠ°Β»*
Π’Π°ΠΊΠΆΠ΅ Π΅ΡΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅, ΠΊΠ΅ΠΌ ΠΎΠ½ΠΈ ΡΠ°Π±ΠΎΡΠ°Π»ΠΈ.
[Read more...](https://lifehacker.ru/skolko-zarabatyvali-makkalistery/)
Π’Π°ΠΊΠΆΠ΅ Π΅ΡΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠ΅, ΠΊΠ΅ΠΌ ΠΎΠ½ΠΈ ΡΠ°Π±ΠΎΡΠ°Π»ΠΈ.
[Read more...](https://lifehacker.ru/skolko-zarabatyvali-makkalistery/)
*ΠΠΎΠ΄ΠΎΡΠ²Ρ ΠΊΡΠΎΡΡΠΎΠ²ΠΎΠΊ*
Π€ΠΈΡΠ½Π΅Ρ, Π±Π΅Π³, ΠΊΠΎΠΌΠ°Π½Π΄Π½ΡΠ΅ Π²ΠΈΠ΄Ρ ΡΠΏΠΎΡΡΠ°, ΠΏΠ°ΡΠΊΡΡ, Π·Π°Π½ΡΡΠΈΡ Π² Π·Π°Π»Π΅ ΠΈ Π½Π° ΡΠ»ΠΈΡΠ΅ ΡΡΠ΅Π±ΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ° ΠΏΠΎΠ΄ΠΎΡΠ²Ρ ΡΠΏΠΎΡΡΠΈΠ²Π½ΠΎΠΉ ΠΎΠ±ΡΠ²ΠΈ. ΠΠ°ΠΏΡΠΈΠΌΠ΅Ρ, Π±Π°ΡΠΊΠ΅ΡΠ±ΠΎΠ»ΡΠ½ΡΠ΅ ΠΊΡΠΎΡΡΠΎΠ²ΠΊΠΈ Π΄Π»Ρ ΡΠ»ΠΈΡΡ ΠΈΠΌΠ΅ΡΡ ΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡ Π² Π²ΠΈΠ΄Π΅ Π΅Π»ΠΎΡΠΊΠΈ , ΠΈΠ½Π°ΡΠ΅ ΠΈΠ³ΡΠΎΠΊ Π±ΡΠ΄Π΅Ρ ...via forma full 5 https://ift.tt/x2XcPMn Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3580841.html)
Π€ΠΈΡΠ½Π΅Ρ, Π±Π΅Π³, ΠΊΠΎΠΌΠ°Π½Π΄Π½ΡΠ΅ Π²ΠΈΠ΄Ρ ΡΠΏΠΎΡΡΠ°, ΠΏΠ°ΡΠΊΡΡ, Π·Π°Π½ΡΡΠΈΡ Π² Π·Π°Π»Π΅ ΠΈ Π½Π° ΡΠ»ΠΈΡΠ΅ ΡΡΠ΅Π±ΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ° ΠΏΠΎΠ΄ΠΎΡΠ²Ρ ΡΠΏΠΎΡΡΠΈΠ²Π½ΠΎΠΉ ΠΎΠ±ΡΠ²ΠΈ. ΠΠ°ΠΏΡΠΈΠΌΠ΅Ρ, Π±Π°ΡΠΊΠ΅ΡΠ±ΠΎΠ»ΡΠ½ΡΠ΅ ΠΊΡΠΎΡΡΠΎΠ²ΠΊΠΈ Π΄Π»Ρ ΡΠ»ΠΈΡΡ ΠΈΠΌΠ΅ΡΡ ΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡ Π² Π²ΠΈΠ΄Π΅ Π΅Π»ΠΎΡΠΊΠΈ , ΠΈΠ½Π°ΡΠ΅ ΠΈΠ³ΡΠΎΠΊ Π±ΡΠ΄Π΅Ρ ...via forma full 5 https://ift.tt/x2XcPMn Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3580841.html)
Forma-Odezhda
ΠΠΎΠ΄ΠΎΡΠ²Ρ ΠΊΡΠΎΡΡΠΎΠ²ΠΎΠΊ - ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠΎΠ΄ΠΎΡΠ²Ρ ΠΊΡΠΎΡΡΠΎΠ²ΠΎΠΊ - ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ°*
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠΈ ΠΠ΅ΡΠΌΠ°Π½ΠΈΠΈ ΠΠ· Π²ΡΠ΅Ρ Π·Π°ΠΏΠ°Π΄Π½ΡΡ ΡΡΡΠ°Π½ ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ ΠΈΠΌΠ΅Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΠΎΠΏΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΡ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠ½ΡΡ ΡΠ°ΡΡΠ²Π΅ΡΠΎΠΊ. Π‘ΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠ΅ΡΠ²ΡΠΉ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆ Ρ Π½Π΅ΠΌΡΠ΅Π² ΠΏΠΎΡΠ²ΠΈΠ»ΡΡ Π΅ΡΠ΅ Π² ΠΠ΅ΡΠ²ΡΡ ΠΌΠΈΡΠΎΠ²ΡΡ.via forma full 5 https://ift.tt/vG0KueX Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3587026.html)
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠΈ ΠΠ΅ΡΠΌΠ°Π½ΠΈΠΈ ΠΠ· Π²ΡΠ΅Ρ Π·Π°ΠΏΠ°Π΄Π½ΡΡ ΡΡΡΠ°Π½ ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ ΠΈΠΌΠ΅Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΠΎΠΏΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΡ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠ½ΡΡ ΡΠ°ΡΡΠ²Π΅ΡΠΎΠΊ. Π‘ΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠ΅ΡΠ²ΡΠΉ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆ Ρ Π½Π΅ΠΌΡΠ΅Π² ΠΏΠΎΡΠ²ΠΈΠ»ΡΡ Π΅ΡΠ΅ Π² ΠΠ΅ΡΠ²ΡΡ ΠΌΠΈΡΠΎΠ²ΡΡ.via forma full 5 https://ift.tt/vG0KueX Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
[Read more...](https://analogindex.livejournal.com/3587026.html)
Forma-Odezhda
ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ°
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ° Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΠΎΠ΄ΠΎΡΠ²Ρ ΠΊΡΠΎΡΡΠΎΠ²ΠΎΠΊ
Π€ΠΈΡΠ½Π΅Ρ, Π±Π΅Π³, ΠΊΠΎΠΌΠ°Π½Π΄Π½ΡΠ΅ Π²ΠΈΠ΄Ρ ΡΠΏΠΎΡΡΠ°, ΠΏΠ°ΡΠΊΡΡ, Π·Π°Π½ΡΡΠΈΡ Π² Π·Π°Π»Π΅ ΠΈ Π½Π° ΡΠ»ΠΈΡΠ΅ ΡΡΠ΅Π±ΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ° ΠΏΠΎΠ΄ΠΎΡΠ²Ρ ΡΠΏΠΎΡΡΠΈΠ²Π½ΠΎΠΉ ΠΎΠ±ΡΠ²ΠΈ. ΠΠ°ΠΏΡΠΈΠΌΠ΅Ρ, Π±Π°ΡΠΊΠ΅ΡΠ±ΠΎΠ»ΡΠ½ΡΠ΅ ΠΊΡΠΎΡΡΠΎΠ²ΠΊΠΈ Π΄Π»Ρ ΡΠ»ΠΈΡΡ ΠΈΠΌΠ΅ΡΡ ΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡ Π² Π²ΠΈΠ΄Π΅ Π΅Π»ΠΎΡΠΊΠΈ , ΠΈΠ½Π°ΡΠ΅ ΠΈΠ³ΡΠΎΠΊ Π±ΡΠ΄Π΅Ρ ...via forma full 5 https://ift.tt/x2XcPMn Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Π€ΠΈΡΠ½Π΅Ρ, Π±Π΅Π³, ΠΊΠΎΠΌΠ°Π½Π΄Π½ΡΠ΅ Π²ΠΈΠ΄Ρ ΡΠΏΠΎΡΡΠ°, ΠΏΠ°ΡΠΊΡΡ, Π·Π°Π½ΡΡΠΈΡ Π² Π·Π°Π»Π΅ ΠΈ Π½Π° ΡΠ»ΠΈΡΠ΅ ΡΡΠ΅Π±ΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ° ΠΏΠΎΠ΄ΠΎΡΠ²Ρ ΡΠΏΠΎΡΡΠΈΠ²Π½ΠΎΠΉ ΠΎΠ±ΡΠ²ΠΈ. ΠΠ°ΠΏΡΠΈΠΌΠ΅Ρ, Π±Π°ΡΠΊΠ΅ΡΠ±ΠΎΠ»ΡΠ½ΡΠ΅ ΠΊΡΠΎΡΡΠΎΠ²ΠΊΠΈ Π΄Π»Ρ ΡΠ»ΠΈΡΡ ΠΈΠΌΠ΅ΡΡ ΠΏΡΠΎΡΠ΅ΠΊΡΠΎΡ Π² Π²ΠΈΠ΄Π΅ Π΅Π»ΠΎΡΠΊΠΈ , ΠΈΠ½Π°ΡΠ΅ ΠΈΠ³ΡΠΎΠΊ Π±ΡΠ΄Π΅Ρ ...via forma full 5 https://ift.tt/x2XcPMn Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠΎΠ΄ΠΎΡΠ²Ρ ΠΊΡΠΎΡΡΠΎΠ²ΠΎΠΊ - ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠΎΠ΄ΠΎΡΠ²Ρ ΠΊΡΠΎΡΡΠΎΠ²ΠΎΠΊ - ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ°
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠΈ ΠΠ΅ΡΠΌΠ°Π½ΠΈΠΈ ΠΠ· Π²ΡΠ΅Ρ Π·Π°ΠΏΠ°Π΄Π½ΡΡ ΡΡΡΠ°Π½ ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ ΠΈΠΌΠ΅Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΠΎΠΏΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΡ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠ½ΡΡ ΡΠ°ΡΡΠ²Π΅ΡΠΎΠΊ. Π‘ΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠ΅ΡΠ²ΡΠΉ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆ Ρ Π½Π΅ΠΌΡΠ΅Π² ΠΏΠΎΡΠ²ΠΈΠ»ΡΡ Π΅ΡΠ΅ Π² ΠΠ΅ΡΠ²ΡΡ ΠΌΠΈΡΠΎΠ²ΡΡ.via forma full 5 https://ift.tt/vG0KueX Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠΈ ΠΠ΅ΡΠΌΠ°Π½ΠΈΠΈ ΠΠ· Π²ΡΠ΅Ρ Π·Π°ΠΏΠ°Π΄Π½ΡΡ ΡΡΡΠ°Π½ ΠΠ΅ΡΠΌΠ°Π½ΠΈΡ ΠΈΠΌΠ΅Π΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΠΎΠΏΡΡ ΡΠΎΠ·Π΄Π°Π½ΠΈΡ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΡ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆΠ½ΡΡ ΡΠ°ΡΡΠ²Π΅ΡΠΎΠΊ. Π‘ΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎ, ΠΏΠ΅ΡΠ²ΡΠΉ ΠΊΠ°ΠΌΡΡΠ»ΡΠΆ Ρ Π½Π΅ΠΌΡΠ΅Π² ΠΏΠΎΡΠ²ΠΈΠ»ΡΡ Π΅ΡΠ΅ Π² ΠΠ΅ΡΠ²ΡΡ ΠΌΠΈΡΠΎΠ²ΡΡ.via forma full 5 https://ift.tt/vG0KueX Manage Unsubscribe from these notifications or sign in to manage your Email service.IFTTT Manage on IFTTT: https://ifttt.com/myrecipes/personal/114580525
Read more...
Forma-Odezhda
ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ°
Π£Π·Π½Π°ΠΉΡΠ΅ ΠΎ ΠΠ°ΠΌΡΡΠ»ΡΠΆΠΈ Π°ΡΠΌΠΈΠΉ ΠΌΠΈΡΠ° Π² ΡΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π€ΠΎΡΠΌΠ° ΠΎΠ΄Π΅ΠΆΠ΄Ρ.
*what the fuck is going down on twitch*
submitted by /u/mythril- to r/shitposting [link] [comments]
[Read more...](https://www.reddit.com/r/shitposting/comments/18oavqz/what_the_fuck_is_going_down_on_twitch/)
submitted by /u/mythril- to r/shitposting [link] [comments]
[Read more...](https://www.reddit.com/r/shitposting/comments/18oavqz/what_the_fuck_is_going_down_on_twitch/)
Reddit
[Mature Content] From the shitposting community on Reddit: what the fuck is going down on twitch
Posted by mythril- - 15,153 votes and 367 comments
what the fuck is going down on twitch
submitted by /u/mythril- to r/shitposting link comments
Read more...
submitted by /u/mythril- to r/shitposting link comments
Read more...
Reddit
[Mature Content] From the shitposting community on Reddit: what the fuck is going down on twitch
Posted by mythril- - 15,153 votes and 367 comments
*Dear fucking god*
submitted by /u/infinitysaga to r/Gamingcirclejerk [link] [comments]
[Read more...](https://www.reddit.com/r/Gamingcirclejerk/comments/18obeg7/dear_fucking_god/)
submitted by /u/infinitysaga to r/Gamingcirclejerk [link] [comments]
[Read more...](https://www.reddit.com/r/Gamingcirclejerk/comments/18obeg7/dear_fucking_god/)
Reddit
From the Gamingcirclejerk community on Reddit: Dear fucking god
Explore this post and more from the Gamingcirclejerk community